You are here: Home / Research / Upcoming Seminars

Upcoming Seminars

Ganna Panasyuk, PhD - "Growth and Metabolic Control by PI3K Signalling"

Necker Enfants Malades Institute (INEM), Inserm, Faculté de Médecine Paris Descartes, Paris, France
When Nov 22, 2018
from 12:00 PM to 01:30 PM
Where Tigem, Vesuvius Auditorium
Contact Name
Contact Phone 081-19230659
Add event to calendar vCal
iCal

Short CV

Abstract
The research interests of my team belong to a fast evolving field on the crossroads of physiology, signal transduction and metabolism. Our overarching aim is to elucidate molecular mechanisms of metabolic control and its implication in human disease. Metabolic misbalance accompanies and contributes to a number of pathological conditions including so prevailing today obesity, type 2 diabetes and cancer. We focus on evolutionary conserved signalling cascade of Insulin Receptor and Phosphoinositide 3-Kinase (PI3K) in physiology and its implication in pathologies such as fatty liver disease, lysosomal storage disease and liver cancer. In this seminar, I will present our recent findings on the metabolic outcomes of interrogating hepatic pro-anabolic class 1 PI3K signalling and pro-catabolic class 3 PI3K signalling. I will also share our unpublished observations on the transcriptional control of liver metabolism by class 3 PI3K in adaptation to fasting.

Daniel Ory, MD - "Niemann-Pick C: A Disorder of Cholesterol Homeostasis"

Senior VP, Translational Medicine, Casma Therapeutics, Cambridge, MA (USA)
When Nov 27, 2018
from 12:00 PM to 01:30 PM
Where Tigem Auditorium "Vesuvius"
Contact Name
Contact Phone 08119230659
Add event to calendar vCal
iCal

Short CV

Abstract
Niemann-Pick type C1 (NPC1) disease is an autosomal recessive neurovisceral disease characterized by progressive lipid accumulation. Mutations in NPC1 (95% of NPC cases) and NPC2 are responsible for NPC in humans. Diagnosis of the disease has been challenging, often leading to diagnostic delays of more than 4-5 years. Therapeutic options are limited. The only approved therapy for NPC is miglustat, an inhibitor of glycosphingolipid synthesis that has shown limited efficacy. In this seminar, advances in NPC diagnostics and treatments will be presented.